Desmoplastic melanoma, a rare form of skin cancer, is characterized by a high tumor mutational burden and is likely to benefit from treatment with immune checkpoint inhibitors. Results from a phase 2 clinical trial now suggest the efficacy of single-agent PD-1 blockade in the treatment of both resectable and unresectable desmoplastic melanoma.
- George Mo
- Tara C. Mitchell
